ReviewNature reviews. Gastroenterology & hepatology2009
Intestinal fibrosis in IBD--a dynamic, multifactorial process.
Review in Nature reviews. Gastroenterology & hepatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
192 citing papers in PubMed, 2 syntheses or guidelines pooled it, 333 citations in OpenAlex.
- Management of ileocolic anastomotic strictures in Crohn's disease: endoscopic or surgical intervention? A systematic review and meta-analysis.International journal of colorectal disease · 2025Pooled it
- Pooled it
- Efficacy, Safety, and Long-term Outcome of Serial Endoscopic Balloon Dilation for Upper Gastrointestinal Crohn's Disease-associated Strictures-A Cohort Study.Journal of Crohn's & colitis · 2017Trial
- A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.Gut microbes · 2026Article
- Intestinal Fibrosis in IBD: Rethinking the Inflammatory Paradigm and Emerging Therapeutic Opportunities.Digestive diseases and sciences · 2026Review
- Human inflammatory bowel disease-on-a-chip for modelling disease progression, cancer initiation and sex-specific effects.Nature biomedical engineering · 2026Article
- Wall stiffening is a primary contributor to motility loss in Crohn's disease: an electromechanical modeling study.bioRxiv : the preprint server for biology · 2026Article
- Microbial 10-oxostearic acid protects mice against colitis via the nuclear receptor PPARα.Nature microbiology · 2026Article
- Almond-Derived Peptide Fraction Alleviates DSS-Induced Colitis with Associated Anti-Inflammatory, Antioxidant, and Barrier-Restorative Effects.Foods (Basel, Switzerland) · 2026Article
- A Bifunctional T3SS-Effector Simultaneously Cleaves Host MAP Kinase and Inhibits PPM1A Phosphatase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Inflammatory bowel disease and extracellular matrix: when victim becomes double agent.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- IL1βJournal of translational medicine · 2026Article
- Developing a protocol to counteract spontaneous in vitro activation of intestinal fibroblasts using design of experiments.npj biomedical innovations · 2026Article
- Multiomics integration of single-cell transcriptomics and bulk sequencing data identifies key biomarkers and predictive models for IBD subtype classification.Frontiers in medicine · 2026Article
- T-cadherin as a potential novel regulator of intestinal inflammation and fibrosis.Frontiers in physiology · 2026Review
- GB20-5A8-31, an anti-TL1A antibody for treating inflammatory bowel disease.Frontiers in immunology · 2026Article
- Developing a Cell Culture Protocol to Induce Quiescence in Intestinal Fibroblasts Using Design of Experiments Statistical Optimization.Research square · 2025Article
- Discordance between MR enterography and endoscopic detection of Crohn's disease ileal strictures: evidence to inform recommendations.Abdominal radiology (New York) · 2025Article
- Molecular Basis of Chronic Intestinal Wall Fibrosis in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025Review
132 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal fibrosis is a common and potentially serious complication of IBD that results from the reaction of intestinal tissue to the damage inflicted by chronic inflammation. The traditional view that fibrosis is inevitable or irreversible in patients with IBD is progressively changing in light of improved understanding of the cellular and molecular mechanisms that underlie the pathogenesis of fibrosis in general, and, in particular, intestinal fibrosis. These mechanisms are complex and dynamic, and involve multiple cell types, interconnected cellular events and a large number of soluble factors. In addition, owing to a breakdown of the epithelial barrier during inflammation of the gut, luminal bacterial products induce an innate immune response, which is triggered by activation of immune and nonimmune cells alike. Comprehension of the mechanisms of intestinal fibrosis will create a conceptual and practical framework that could achieve the specific blockade of fibrogenic pathways, allow for the estimation of risk of fibrotic complications, permit the detection of early fibrotic changes and, eventually, enable the development of treatments customized to the type and stage of each patient's IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.